If localized CRC patients with MT KRAS had more chances of recurrence, then the MT KRAS cases would be selected and thus a higher frequency of MT KRAS in recurrent CRC patients would be expected than in patients with stage IV disease at the time of initial CRC diagnosis. This evidence concerns the gene KRAS and colorectal carcinoma.